SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Artelo Biosciences to Present ART27.13 Data at IASP 2026 Congress

The company says nonclinical studies showed reductions in two measures of neuropathic pain; a Phase 2 study is ongoing.

ARTL

Story updates

01:06:54 PM UTC
SquawkNews
Nonclinical studies demonstrated reductions in two key measures of neuropathic painOngoing Phase 2 CAReS trial includes pain endpoints to evaluate ART27.13's potential to address multiple cancer-related symptomsSOLANA BEACH, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. NASDAQ…

Related stories